A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.

Tytuł:: A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.
Autorzy:: Ruzzolini J; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Laurenzana A; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Andreucci E; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Peppicelli S; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Bianchini F; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Carta F; Department of NEUROFARBA, University of Florence, Florence, Italy.
Supuran CT; Department of NEUROFARBA, University of Florence, Florence, Italy.
Romanelli MN; Department of NEUROFARBA, University of Florence, Florence, Italy.
Nediani C; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Calorini L; Department of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.; Center of Excellence for Research, Transfer and High Education, DenoTHE University of Florence, Florence, Italy.
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2020 Dec; Vol. 35 (1), pp. 391-397.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Basingstoke, UK : Taylor & Francis, c2002-
MeSH Terms:: Antineoplastic Agents/*pharmacology
Carbonic Anhydrase IX/*antagonists & inhibitors
Carbonic Anhydrase Inhibitors/*pharmacology
Histone Deacetylase Inhibitors/*pharmacology
Histone Deacetylases/*metabolism
Phenylurea Compounds/*pharmacology
Sulfonamides/*pharmacology
Antigens, Neoplasm/metabolism ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Carbonic Anhydrase IX/metabolism ; Carbonic Anhydrase Inhibitors/chemical synthesis ; Carbonic Anhydrase Inhibitors/chemistry ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Histone Deacetylase Inhibitors/chemical synthesis ; Histone Deacetylase Inhibitors/chemistry ; Humans ; Molecular Structure ; Phenylurea Compounds/chemical synthesis ; Phenylurea Compounds/chemistry ; Structure-Activity Relationship ; Sulfonamides/chemical synthesis ; Sulfonamides/chemistry ; Tumor Cells, Cultured
References:: Chem Commun (Camb). 2012 Sep 11;48(70):8838-40. (PMID: 22836518)
Molecules. 2018 Apr 30;23(5):. (PMID: 29710858)
Haematologica. 2009 Oct;94(10):1375-82. (PMID: 19794082)
J Med Chem. 2003 Nov 20;46(24):5097-116. (PMID: 14613312)
Adv Exp Med Biol. 2014;812:19-24. (PMID: 24729210)
Bioorg Med Chem Lett. 2008 Sep 15;18(18):5071-4. (PMID: 18723349)
Nat Biotechnol. 2012 Jul 10;30(7):679-92. (PMID: 22781697)
Nat Rev Cancer. 2013 Oct;13(10):714-26. (PMID: 24060863)
Curr Opin Struct Biol. 2016 Dec;41:145-150. (PMID: 27521655)
Cell Cycle. 2015;14(19):3088-100. (PMID: 26496168)
J Pathol. 2008 Dec;216(4):495-504. (PMID: 18850582)
Chem Biol Interact. 2009 May 15;179(2-3):169-77. (PMID: 19070610)
Oncol Rep. 2016 May;35(5):2499-515. (PMID: 26986034)
Int J Cancer. 2017 Sep 15;141(6):1190-1200. (PMID: 28577299)
Expert Opin Ther Pat. 2018 Oct;28(10):729-740. (PMID: 30074415)
Cancer Lett. 2017 Nov 1;408:43-54. (PMID: 28826720)
Front Pharmacol. 2017 Dec 12;8:911. (PMID: 29311921)
Anticancer Res. 2017 Jan;37(1):35-46. (PMID: 28011471)
J Enzyme Inhib Med Chem. 2018 Dec;33(1):485-495. (PMID: 29390912)
Front Oncol. 2016 Mar 29;6:69. (PMID: 27066453)
Drug Discov Today. 2016 Feb;21(2):225-38. (PMID: 26360051)
J Med Chem. 2000 Oct 5;43(20):3677-87. (PMID: 11020282)
Biomol Ther (Seoul). 2018 Jan 1;26(1):39-44. (PMID: 29212305)
Int J Mol Sci. 2019 May 15;20(10):. (PMID: 31096697)
Cancer Lett. 2015 Nov 1;368(1):7-13. (PMID: 26276713)
Metabolites. 2017 Dec 23;8(1):. (PMID: 29295495)
Clin Cancer Res. 2003 Feb;9(2):802-11. (PMID: 12576453)
EBioMedicine. 2019 Jan;39:194-206. (PMID: 30611716)
Oncologist. 2007 Oct;12(10):1247-52. (PMID: 17962618)
Mol Cancer Ther. 2016 Jun;15(6):1155-62. (PMID: 26983881)
Nature. 2011 Nov 23;480(7377):387-90. (PMID: 22113612)
Nat Rev Cancer. 2002 Jan;2(1):48-58. (PMID: 11902585)
Nat Biotechnol. 2009 Jul;27(7):659-66. (PMID: 19581876)
Cancer Treat Rev. 2003 Dec;29(6):541-9. (PMID: 14585264)
Oncogene. 2010 Aug 26;29(34):4741-51. (PMID: 20531305)
J Enzyme Inhib Med Chem. 2019 Dec;34(1):117-123. (PMID: 30362384)
Gynecol Oncol. 2010 Jan;116(1):126-30. (PMID: 19875160)
Jpn Dent Sci Rev. 2018 Feb;54(1):8-21. (PMID: 29628997)
J Cell Mol Med. 2012 Aug;16(8):1758-65. (PMID: 22004558)
Int J Cancer. 2009 Mar 1;124(5):1235-44. (PMID: 19058176)
Metabolites. 2017 Sep 16;7(3):. (PMID: 28926956)
Cell Mol Life Sci. 2017 Aug;74(15):2761-2771. (PMID: 28331999)
Oncogene. 2007 Aug 13;26(37):5541-52. (PMID: 17694093)
Trends Pharmacol Sci. 2013 Dec;34(12):656-66. (PMID: 24210882)
BMC Cancer. 2017 Feb 24;17(1):156. (PMID: 28235409)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Expert Opin Investig Drugs. 2018 Dec;27(12):963-970. (PMID: 30426805)
PLoS One. 2013;8(3):e58267. (PMID: 23469273)
Clin Exp Metastasis. 2018 Apr;35(4):309-318. (PMID: 29799080)
Expert Opin Drug Discov. 2017 Jan;12(1):61-88. (PMID: 27783541)
J Mol Med (Berl). 2017 Dec;95(12):1341-1353. (PMID: 28929255)
ISRN Biochem. 2014 Apr 10;2014:351959. (PMID: 25937967)
EMBO Rep. 2014 Dec;15(12):1243-53. (PMID: 25381661)
Contributed Indexing:: Keywords: Carbonic anhydrase IX; SLC-0111;SAHA; combined therapy; histone acetylation
Substance Nomenclature:: 0 (Antigens, Neoplasm)
0 (Antineoplastic Agents)
0 (Carbonic Anhydrase Inhibitors)
0 (Histone Deacetylase Inhibitors)
0 (Phenylurea Compounds)
0 (SLC-0111)
0 (Sulfonamides)
EC 3.5.1.98 (Histone Deacetylases)
EC 4.2.1.1 (CA9 protein, human)
EC 4.2.1.1 (Carbonic Anhydrase IX)
Entry Date(s):: Date Created: 20191224 Date Completed: 20200214 Latest Revision: 20231113
Update Code:: 20240105
PubMed Central ID:: PMC6968260
DOI:: 10.1080/14756366.2019.1706090
PMID:: 31865754
: Czasopismo naukowe

Pełny tekst

The emergence of tumour recurrence and resistance limits the survival rate for most tumour-bearing patients. Only, combination therapies targeting pathways involved in the induction and in the maintenance of cancer growth and progression might potentially result in an enhanced therapeutic efficacy. Herein, we provided a prospective combination treatment that includes suberoylanilide hydroxamic acid (SAHA), a well-known inhibitor of histone deacetylases (HDACs), and SLC-0111, a novel inhibitor of carbonic anhydrase (CA) IX. We proved that HDAC inhibition with SAHA in combination with SLC-0111 affects cell viability and colony forming capability to greater extent than either treatment alone of breast, colorectal and melanoma cancer cells. At the molecular level, this therapeutic regimen resulted in a synergistically increase of histone H4 and p53 acetylation in all tested cell lines. Overall, our findings showed that SAHA and SLC-0111 can be regarded as very attractive combination providing a potential therapeutic strategy against different cancer models.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja